{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:33:02Z","timestamp":1786984382636,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.annonc.2025.03.011","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T18:57:08Z","timestamp":1742756228000},"page":"749-761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enrichment of CD7+CXCR3+ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6875-6734","authenticated-orcid":false,"given":"R.","family":"Bartolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Trueb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-9253","authenticated-orcid":false,"given":"D.","family":"Daoudlarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stadelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gentner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Perreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Coukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2025.03.011_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.03.011_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.annonc.2025.03.011_bib3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.annonc.2025.03.011_bib4","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.annonc.2025.03.011_bib5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.annonc.2025.03.011_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.annonc.2025.03.011_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.03.011_bib8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.annonc.2024.12.004","article-title":"Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy","volume":"36","author":"Daoudlarian","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.03.011_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","article-title":"Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study","volume":"36","author":"Petit","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.03.011_bib10","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1038\/s41467-024-47965-3","article-title":"Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma","volume":"15","author":"Joo","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.annonc.2025.03.011_bib11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.annonc.2025.03.011_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.annonc.2025.03.011_bib13","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.annonc.2025.03.011_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.annonc.2025.03.011_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.03.011_bib16","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.annonc.2025.03.011_bib17","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","article-title":"CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells","volume":"11","author":"Zhang","year":"2017","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.03.011_bib18","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41467-019-11893-4","article-title":"Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56","volume":"10","author":"Zou","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.annonc.2025.03.011_bib19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.annonc.2025.03.011_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.annonc.2025.03.011_bib21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.annonc.2025.03.011_bib22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fimmu.2020.00702","article-title":"Prolonged persistence of chimeric antigen receptor (CAR) T cell in adoptive cancer immunotherapy: challenges and ways forward","volume":"11","author":"Jafarzadeh","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.annonc.2025.03.011_bib23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","article-title":"NKG2D receptor and its ligands in host defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.03.011_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40164-024-00553-z","article-title":"Efficacy of NKG2D CAR-T cells with IL-15\/IL-15Ralpha signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder","volume":"13","author":"Mai","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"26","key":"10.1016\/j.annonc.2025.03.011_bib25","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342500122X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342500122X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:01:33Z","timestamp":1752573693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342500122X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S092375342500122X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.03.011","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enrichment of CD7+CXCR3+ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}